8.43
0.16 (1.93%)
| Previous Close | 8.27 |
| Open | 8.21 |
| Volume | 5,595,717 |
| Avg. Volume (3M) | 8,657,500 |
| Market Cap | 2,890,085,888 |
| Price / Sales | 110.02 |
| Price / Book | 9.11 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Operating Margin (TTM) | -1,913.23% |
| Diluted EPS (TTM) | -2.20 |
| Total Debt/Equity (MRQ) | 2.72% |
| Current Ratio (MRQ) | 9.01 |
| Operating Cash Flow (TTM) | -157.34 M |
| Levered Free Cash Flow (TTM) | -64.76 M |
| Return on Assets (TTM) | -23.33% |
| Return on Equity (TTM) | -119.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nuvation Bio Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 19.14% |
| % Held by Institutions | 62.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 25,954,439 |
| Laurion Capital Management Lp | 30 Sep 2025 | 9,705,532 |
| Omega Fund Management, Llc | 30 Sep 2025 | 8,831,089 |
| Tang Capital Management Llc | 30 Sep 2025 | 4,200,000 |
| Abrams Capital Management, L.P. | 30 Sep 2025 | 3,811,513 |
| Aisling Capital Management Lp | 30 Sep 2025 | 2,960,659 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (HC Wainwright & Co., 113.52%) | Buy |
| Median | 10.00 (18.62%) | |
| Low | 6.00 (Wedbush, -28.83%) | Buy |
| Average | 10.71 (27.05%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 6.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Dec 2025 | 18.00 (113.52%) | Buy | 8.27 |
| 01 Dec 2025 | 10.00 (18.62%) | Buy | 7.88 | |
| Truist Securities | 24 Nov 2025 | 11.00 (30.49%) | Buy | 7.41 |
| Citizens | 20 Nov 2025 | 10.00 (18.62%) | Buy | 7.01 |
| 04 Nov 2025 | 8.00 (-5.10%) | Buy | 4.83 | |
| B. Riley Securities | 19 Nov 2025 | 12.00 (42.35%) | Buy | 7.15 |
| RBC Capital | 04 Nov 2025 | 8.00 (-5.10%) | Buy | 4.83 |
| Wedbush | 13 Oct 2025 | 6.00 (-28.83%) | Buy | 3.68 |
| Jefferies | 30 Sep 2025 | 10.00 (18.62%) | Buy | 3.70 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |